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Background: The past decade has been a lean period for the dis-
covery of antibiotics with very few approvals of new antibacterial
agents by FDA. However, emergence ofMulti Drug Resistant organ-
isms (MDRO) and Extensively Drug Resistant organisms (XDRO)
pathogens have led to increased attention to this ﬁeld. Center
for Disease Control and Prevention (CDC) has declared infections
caused by MDR ESKAPE pathogens as a critical area of unmet med-
ical need. Further, FDA has also announced various incentives to
support the Infectious Diseases Society of America (IDSA) aspira-
tion to develop 10 new antibiotics by 2020. In this presentation, I
will discuss challenges in the discovery of antibacterial compounds
with a case study of Leucine tRNA synthetase inhibitor (LRSI).
Methods & Materials: Various properties of antibacterial stan-
dard of care agents analyzed with respect to physicochemical,
safety and activity against MDROs/XDROs. Also, merits and demer-
its of novel targets vs. novel approaches were considered. In order
to explore novel targets we have designed, synthesized & pro-
ﬁled novel LRSI. The proﬁle of our compound was compared with
reported LRSI to identify the differentials.
Results: Unlike general drugs, antibacterial compounds need
distinct physicochemical properties in order to work efﬁciently
in different cellular milieu of host & pathogen. Safety (selectiv-
ity & toxicity) is critical as doses required to control the infection
are usually high. New compounds should not only be effective
against MDROs but also possess lower risk of resistance develop-
ment and relapse. We have identiﬁed novel selective Leucine tRNA
synthetase inhibitor (LRSI) for Gram negative MDROs. On analysis
this compound showsdistinct advantages over previously reported
inhibitor.
Conclusion: To circumvent the challenges in the discovery
of antibacterial compounds, the Pharma industry recognizes the
need of novel targets and approaches to tackle the ever evolving
pathogens. Towards this pursuitwe identiﬁed anovel Leucine tRNA
synthetase inhibitor (LRSI) with potent activity against MDROs.
Promising proﬁle of this novel inhibitor merits further develop-
ment for clinical use.
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Antimicrobial resistance: From problem to
policy to action
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Abstract: Professor Dame Sally Davies, Chief Medical Ofﬁcer
for England, will set out why Antimicrobial Resistance (AMR) has
become a Global Health Security issue.
She will explain how, through our collective action, AMR has
become a signiﬁcant health issue across the globe and the impact
on health if we do not take collective action to conserve the antimi-
crobials that we have, and encourage the development of new
antimicrobials.
Dame Sally will highlight the need for cross-government
engagement in the ﬁght against AMR – it cannot be seen as a health
issue in isolation, but needs a ‘one-health’ approach.
Finally, Dame Sally will consider the challenges that we face
globally, the international action to date and important next steps.
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Abstract: The number and complexity of tissues being trans-
planted worldwide has increased, which has been made possible
by more centers and well trained teams being involved, and bet-
ter availability of organs. Increasedunderstandingof theworkingof
the immune system, andmore choices in drugs has ensured greater
graft survival with fewer long term complications. Simultaneously,
advances in infection control, and targeted use of prophylactic
agents has resulted in improved overall survival due to reduction in
infections. However, this has resulted in the rise in relative impor-
tance of fungal infections as a cause of morbidity and mortality in
transplant recipients. There have been many advances in this ﬁeld,
and this startswith risk reduction.Betterunderstandingon the time
line of fungal infections have helped us design enhanced infection
control measures like HEPA ﬁlter in stem cell recipients, patient
education on avoidance of high risk situations, a commitment to
de-escalate immune suppression and use of targeted antifungal
prophylaxis. In spite of such interventions, fungal infections con-
tinue to play a role. Early identiﬁcation of patients who are at risk
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for invasive fungal infection can ensure use of pre emptive therapy
in selected cases. Better diagnostic modalities including radiology
like high resolution computed tomogramsof the chest, earlier inva-
sive procedures including bronchoscopy and biopsy coupled with
serological studies like beta d-glucan, and galactomannan have
shortened the time to diagnosis of fungal infections. Simultane-
ously, advances in fungal identiﬁcation, both culture andmolecular
techniques have helped the clinician use themost appropriate anti-
fungal agent.We also have an expanding armamentarium of drugs,
both new drugs in existing classes and a new class of antifungal
agents, to best suit the individual patient. There is still scope for
signiﬁcant improvement in areas, which include evaluation of new
markers which could hasten time to diagnosis, and new agents
which can tackle some of the more difﬁcult or resistant fungi.
http://dx.doi.org/10.1016/j.ijid.2016.02.151
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Abstract: Chemotherapy-induced neutropenia is the leading
cause for bacterial and fungal infections in patients with haema-
tological malignancies. The drop of neutrophyls count below 1000
cells/cmm increase the risk of febrile episodes (TC>38 ◦C) and
infectious complications but most of the bacteremic episodes are
documented when neutrophils count is below 100/cmm (severe
neutropenia). The duration of neutropenia also play a pivotal role in
determining the risk of infection: prolonged neutropenia is deﬁned
by a duration of 3 weeks. Among 100 febrile episodes occurring
during neutropenia 40% are FUO, 20% are clinically documented,
20% are microbiologically documented and 20% are bacteremia.
Gram-positive cocci (CNS, St. aureus, streptococci, enterococci)
represent around 50% of the blood isolates and gram-negative
bacilli (Ps. aeruginosa, enterobacteriaceae) are documented in the
same rate. Recently, an increasing rate of MDR gram-negative
bacilli (i.e. K.pneumoniae KPC-producing and other carbapenem-
resistant gram-negative bugs) are responsible for local epidemic
clusters. Empiric antibiotic therapy is recommended in patient
with febrile neutropenia: blood cultures (at least 2 sets) should
be taken immediately and therapy started in 1 hour (febrile
neutropenia is a medical emergency). Monotherapy with a beta-
lactam antibiotic with anti-pseudomonal activity (meropenem,
piperacillin/tazobactam) is usually started, adding an anti gram-
positive agent (vancomycin, daptomycin) in case of a documented
gram-positive bacteremia or in patientwith local sign of CVC infec-
tion (“escalation” strategy). A de-escalation strategy is preferred
in patient presenting with severe sepsis or septic shock and in
the setting of a cluster of MDR gram-negative bacilli. Combination
therapy is started (betalactam, aminoglycoside, antistaphylococcal
agent) then de-escalated on the basis of microbiological docu-
mentation and/or clinical response. In case of KPC-producing K.
pneumoniae epidemic a combination of colistin, tygecicline and
gentamicin should be considered; some clinicians suggest the use
of high-dose meropenem (although many of the isolates shows a
MIC >128 mg/l). It is noteworthy that the use of rectal swab to
identify colonized patients may be important for the infection con-
trol procedures (patient isolation) and to predict the subsequent
sepsis. In neutropenic patients with fever not responding to 3 or 4
days of antibiotic therapy the start of an empiric antifungal therapy
(echinocandin, amphotericin B) should be considered. Serological
markers (betaglucan, mannan/anti-mannan etc.) may be useful to
select patients at higher risk of yeast infection; galactomannan is
otherwise useful to suspect Aspergillus infection.
http://dx.doi.org/10.1016/j.ijid.2016.02.152
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Abstract: An expanding array of new biologics are entering
clinical practice to supplement existing therapies in the man-
agement of neoplastic diseases, organ transplantation, rheumatic
diseases and numerous other inﬂammatory disease states. These
biologics include monoclonal antibodies, soluble cytokine recep-
tor constructs, growth factors and recombinant proteins. Their
use have revolutionized treatment for some severe forms of
rheumatoid arthritis, multiple sclerosis (MS) and inﬂammatory
bowel disease where biologics have now become the stan-
dard of care. Such agents are not without risk as a number
of common infections and at times rather unusual infections
are being recognized with increasing frequency following the
institution of biologics. Opportunistic infections are particu-
larly a concern in patients receiving combination therapy with
multiple biologics in addition to standard immunosuppressive
agents such as corticosteroids, anti-metabolites and calcineurin
inhibitors.
Because of their frequency and severity, the infections of great-
est importance following a biologic are tuberculosis, opportunistic
and endemic mycoses (histoplasmosis and coccidioidomycosis),
and high risk viral infections (HIV, hepatitis B and C, adenoviruses
and the JC virus that causes progressive multifocal leukoen-
cephalopathy (PML). While these infections should receive the
most attention, an array of pathogens ranging from viruses (herpes
viruses, paramyxoviruses), bacteria (e.g. listeriosis, mycobacterial
infections, skin and soft tissue pathogens, respiratory infections),
numerous opportunistic fungi, and parasitic organisms including
toxoplasmosis, pneumocystosis, and strongyloidiasis should also
be considered. The greater the intensity, duration and combina-
tions of biologics all increase the risk of secondary infection. Many
biologics have prolonged immunosuppressive effects, thereby
limiting cost and improving convenience, but this long pharma-
codynamic effect leads to infection risk for prolonged periods
up to years after stopping the treatment. A number of these
infections can be detected in latent forms allowing for pro-
phylaxis or avoidance of some biologics such as screening for
PML by serology before using natalizumab (alpha-4 integrin
